Penetrance estimates for BRCA1 , BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?

Journal of Medical Genetics
D Gareth EvansFiona Lalloo

Abstract

The identification of BRCA1, BRCA2 or mismatch repair (MMR) pathogenic gene variants in familial breast/ovarian/colorectal cancer families facilitates predictive genetic testing of at-risk relatives. However, controversy still exists regarding overall lifetime risks of cancer in individuals testing positive. We assessed the penetrance of BRCA1, BRCA2, MLH1 and MSH2 mutations in men and women using Bayesian calculations based on ratios of positive to negative presymptomatic testing by 10-year age cohorts. Mutation position was also assessed for BRCA1/BRCA2. RESULTS: Using results from 2264 presymptomatic tests in first-degree relatives (FDRs) of mutation carriers in BRCA1 and BRCA2 and 646 FDRs of patients with MMR mutations, we assessed overall associated cancer penetrance to age of 68 years as 73% (95% CI 61% to 82%) for BRCA1, 60% (95% CI 49% to 71%) for BRCA2, 95% (95% CI 76% to 99%) for MLH1% and 61% (95% CI 49% to 76%) for MSH2. There was no evidence for significant penetrance for males in BRCA1 or BRCA2 families and males had equivalent penetrance to females with Lynch syndrome. Mutation position and degree of family history influenced penetrance in BRCA2 but not BRCA1. CONCLUSION: We describe a new method for assessing p...Continue Reading

References

May 15, 1997·The New England Journal of Medicine·J P StruewingM A Tucker
Aug 5, 1999·Journal of the National Cancer Institute·UNKNOWN Breast Cancer Linkage Consortium
Aug 22, 2002·Journal of the National Cancer Institute·Colin B Begg
Oct 25, 2003·Science·Mary-Claire KingUNKNOWN New York Breast Cancer Study Group
May 8, 2004·Familial Cancer·Jan LubinskiSteven A Narod
Sep 6, 2005·Journal of Medical Genetics·C J van AsperenUNKNOWN Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON)
Jan 19, 2006·Journal of the National Cancer Institute·Laufey TryggvadottirJorunn E Eyfjörd
Apr 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sining Chen, Giovanni Parmigiani
Nov 11, 2008·Journal of Medical Genetics·D G R EvansA Howell
Jul 2, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·D Gareth R EvansUNKNOWN UK Study of MRI Screening for Breast Cancer in Women at High Risk (MARIBS)
Aug 8, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·D Gareth R EvansAnthony Howell
May 1, 2013·Journal of the National Cancer Institute·Nasim MavaddatUNKNOWN EMBRACE
Apr 8, 2015·JAMA : the Journal of the American Medical Association·Timothy R RebbeckIrene Andrulis
Jul 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Janet R VosGeertruida H de Bock
Jun 21, 2017·JAMA : the Journal of the American Medical Association·Karoline B KuchenbaeckerHåkan Olsson

❮ Previous
Next ❯

Citations

Sep 27, 2018·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Simone M RowleyIan G Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

© 2022 Meta ULC. All rights reserved